Original Article

You have full text access to this OnlineOpen article

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer

The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial

  1. Luigi Cataliotti M.D.1,
  2. Aman U. Buzdar M.D.2,†,‡,*,
  3. Shinzaburo Noguchi M.D.3,
  4. Jose Bines M.D.4,
  5. Yuichi Takatsuka M.D.5,
  6. Katarina Petrakova M.D.6,
  7. Pierre Dube M.D.7,§,
  8. Celia Tosello de Oliveira M.D.8

Article first published online: 5 APR 2006

DOI: 10.1002/cncr.21872

Issue

Cancer

Cancer

Volume 106, Issue 10, pages 2095–2103, 15 May 2006

Additional Information

How to Cite

Cataliotti, L., Buzdar, A. U., Noguchi, S., Bines, J., Takatsuka, Y., Petrakova, K., Dube, P. and Tosello de Oliveira, C. (2006), Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer. Cancer, 106: 2095–2103. doi: 10.1002/cncr.21872

Author Information

  1. 1

    Clinica Chirurgica 1, University degli Studi di Firenze, Firenze, Italy

  2. 2

    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Department of Breast and Endocrine Surgery, Osaka University Medical School, Osaka, Japan

  4. 4

    Breast Cancer Unit, National Cancer Institute, Rio de Janeiro, Brazil

  5. 5

    Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan

  6. 6

    Department of Oncology, Masaryk Oncological Institute, Brno, Czech Republic

  7. 7

    Department of Surgery, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada

  8. 8

    Departamento de Quimioterapia, Institute Brasileiro de Combate ao Cancer, Sao Paulo, Brazil

  1. †

    Fax: (713) 794-4385

  2. ‡

    Dr. Buzdar has received research grants, travel awards, and honoraria from AstraZeneca.

  3. §

    Dr. Dube has been a Principal Investigator for AstraZeneca, Novartis, and Hoffman LaRoche.

*Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030

Publication History

  1. Issue published online: 27 APR 2006
  2. Article first published online: 5 APR 2006
  3. Manuscript Accepted: 5 JAN 2006
  4. Manuscript Revised: 6 DEC 2005
  5. Manuscript Received: 24 AUG 2005

Funded by

  • AstraZeneca, Wilmington, DE

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (193K)

REFERENCES

  • 1
    Anderson ED, Forrest AP, Levack PA, et al. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer. 1989; 60: 223–226.
  • 2
    Ellis MJ. Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea. Cancer Control. 2000; 7: 557–562.
  • 3
    Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003; 21: 2600–2608.
  • 4
    Preece PE, Wood RA, Mackie CR, et al. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed). 1982; 284: 869–870.
  • 5
    Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: medical perspectives. Clin Cancer Res. 2001; 7: 4388s–4391s.
  • 6
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15: 2483–2493.
  • 7
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 2672–2685.
  • 8
    Gianni L, Baselga J, Eiermann W, et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease [abstract 132]. Proc Am Soc Clin Oncol. 2002; 21: 34a.
  • 9
    Jakesz R, for the the ABCSG. Comparison of pre vs postoperative chemotherapy in breast cancer patients. Four-year results of Austrian Breast Colorectal Cancer Study Group (ABCSG) Trial 7 [abstract 125]. Proc Am Soc Clin Oncol. 2001; 20: 32a.
  • 10
    Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994; 30A: 645–652.
  • 11
    Smith IE, Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol. 2001; 2: 561–570.
  • 12
    van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001; 19: 4224–4237.
  • 13
    Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res. 2000; 6: 2229–2235.
  • 14
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001; 12: 1527–1532.
  • 15
    Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19: 3808–3816.
  • 16
    Harper-Wynne CL, Sacks NP, Shenton K, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol. 2002; 20: 1026–1035.
  • 17
    Mansi JL, Smith IE, Walsh G, et al. Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol. 1989; 25: 1623–1627.
  • 18
    Milla-Santos A, Milla I, Rallo L, et al. Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) patients (pts) [abstract 156]. Proc Am Soc Clin Oncol. 2002; 21: 40a.
  • 19
    Semiglazov V, Semiglazov VV, Ivanov VG, et al. Anastrozole (A) vs tamoxifen (T) vs combine (A + T) as neoadjuvant endocrine therapy of postmenopausal breast cancer patients. Breast. 2003; 12: S39–S87.
  • 20
    Dowsett M, MacNeill F, Mehta A, et al. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer. 1991; 64: 887–894.
  • 21
    Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 1993; 53: 266–270.
  • 22
    Johnston SR, Smith IE, Doody D, et al. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res. 1994; 54: 5875–5881.
  • 23
    Anderson TJ, Dixon JM, Stuart M, et al. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer. 2002; 87: 334–338.
  • 24
    World Health Organization. WHO Classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: International Agency for Research on Cancer (IARC) Press; 2002.
  • 25
    Buzdar A, Robertson JFR, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer. 2002; 95: 2006–2016.
    Direct Link:
  • 26
    Pierce LJ, Hutchins LF, Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005; 23: 24–29.
View Full Article (HTML) Get PDF (193K)